Luo T - Search Results

1

Safety of COVID-19 Vaccination in Patients With Breast Cancer: Cross-Sectional Study in China.

Zhang S, Li J, Xu R, Chen Q, Sun G, Lin Y, Cao Y, Chen Y, Geng C, Teng Y, Nie J, Li X, Xu G, Liu X, Jin F, Fan Z, Luo T, Liu H, Wang FS, Jiang Z. Zhang S, et al. Among authors: luo t. JMIR Public Health Surveill. 2023 Dec 7;9:e46009. doi: 10.2196/46009. JMIR Public Health Surveill. 2023. PMID: 38060302 Free PMC article.

2

Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial.

Xu B, Yan M, Ma F, Hu X, Feng J, Ouyang Q, Tong Z, Li H, Zhang Q, Sun T, Wang X, Yin Y, Cheng Y, Li W, Gu Y, Chen Q, Liu J, Cheng J, Geng C, Qin S, Wang S, Lu J, Shen K, Liu Q, Wang X, Wang H, Luo T, Yang J, Wu Y, Yu Z, Zhu X, Chen C, Zou J; PHOEBE Investigators. Xu B, et al. Among authors: luo t. Lancet Oncol. 2021 Mar;22(3):351-360. doi: 10.1016/S1470-2045(20)30702-6. Epub 2021 Feb 11. Lancet Oncol. 2021. PMID: 33581774 Clinical Trial.

3

Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial.

Ma F, Yan M, Li W, Ouyang Q, Tong Z, Teng Y, Wang Y, Wang S, Geng C, Luo T, Zhong J, Zhang Q, Liu Q, Zeng X, Sun T, Mo Q, Liu H, Cheng Y, Cheng J, Wang X, Nie J, Yang J, Wu X, Wang X, Li H, Ye C, Dong F, Wu S, Zhu X, Xu B; PHILA Investigators. Ma F, et al. Among authors: luo t. BMJ. 2023 Oct 31;383:e076065. doi: 10.1136/bmj-2023-076065. BMJ. 2023. PMID: 37907210 Free PMC article. Clinical Trial.

4

Comparing pyrotinib with trastuzumab and pertuzumab with trastuzumab for HER2-positive metastatic breast cancer: a retrospective, multicenter analysis.

You S, Xie Y, Sang D, Luo T, Yuan P, Xu F, Wang B. You S, et al. Among authors: luo t. Front Endocrinol (Lausanne). 2023 Dec 11;14:1325540. doi: 10.3389/fendo.2023.1325540. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 38149099 Free PMC article.

5

Efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with anthracycline/taxanes.

Chen L, Yan X, Luo T, Tian T, He P, Zhong X. Chen L, et al. Among authors: luo t. Cancer Med. 2024 May;13(10):e7295. doi: 10.1002/cam4.7295. Cancer Med. 2024. PMID: 38785215 Free PMC article.

6

Inhibition of eIF2α dephosphorylation enhances TRAIL-induced apoptosis in hepatoma cells.

Teng Y, Gao M, Wang J, Kong Q, Hua H, Luo T, Jiang Y. Teng Y, et al. Among authors: luo t. Cell Death Dis. 2014 Feb 13;5(2):e1060. doi: 10.1038/cddis.2014.24. Cell Death Dis. 2014. PMID: 24525736 Free PMC article.

7

[Diagnostic value of MDM2 RNA in situ hybridization in atypical lipomatous tumor/well-differentiated liposarcoma and dedifferentiated liposarcoma].

Chen C, He X, Jing WY, Qiu Y, Chen M, Luo TY, Liu XY, Chen HJ, Zhang HY, Bu H. Chen C, et al. Among authors: luo ty. Zhonghua Bing Li Xue Za Zhi. 2022 Mar 8;51(3):190-195. doi: 10.3760/cma.j.cn112151-20211029-00785. Zhonghua Bing Li Xue Za Zhi. 2022. PMID: 35249280 Chinese.

8

A Phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments.

Xu B, Ma F, Wang T, Wang S, Tong Z, Li W, Wu X, Wang X, Sun T, Pan Y, Yao H, Wang X, Luo T, Yang J, Zeng X, Zhao W, Cong XJ, Chen J. Xu B, et al. Among authors: luo t. Int J Cancer. 2023 May 15;152(10):2134-2144. doi: 10.1002/ijc.34424. Epub 2023 Jan 30. Int J Cancer. 2023. PMID: 36621000 Free article.

9

Survival and Trends in Annualized Hazard Function by Age at Diagnosis Among Chinese Breast Cancer Patients Aged ≤40 Years: Case Analysis Study.

Wang J, Luo T, Xiang ZZ, He MM, Zeng YY, Yang T, Wei XY, Yu S, Dai ZL, Xu NY, Tan CF, Liu L. Wang J, et al. Among authors: luo t. JMIR Public Health Surveill. 2023 Jul 18;9:e47110. doi: 10.2196/47110. JMIR Public Health Surveill. 2023. PMID: 37463020 Free PMC article.

10

Real-world data of lapatinib and treatment after lapatinib in patients with previously treated HER2-positive metastatic breast cancer: A multicenter, retrospective study.

Xie Y, Ge R, Sang D, Luo T, Li W, Ji X, Yuan P, Wang B. Xie Y, et al. Among authors: luo t. Cancer Med. 2020 May;9(9):2981-2988. doi: 10.1002/cam4.2943. Epub 2020 Feb 28. Cancer Med. 2020. PMID: 32108439 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

3,657 results

Search Page